LUMO — Lumos Pharma Share News
0.000.00%
Last trade - 00:00- $37.41m
- $23.89m
- $2.05m
Lumos Pharma Inc reports results for the quarter ended in December - Earnings Summary
Brief: Lumos Pharma Reports Full Year 2022 Financial Results, Provides Clinical Development Updates
Brief: Lumos Pharma Completes Patient Enrollment In Two Phase 2 Oragrowth Trials Evaluating Oral Lum-201 In Moderate Idiopathic Pghd
Lumos Pharma Inc expected to post a loss of 93 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP- Armstrong World Industries, Eli Lilly, Netflix
Brief: KOL Review Of Lumos's Interim Mid-Stage Data Supports Potential For New Oral Therapeutic For Moderate Idiopathic PGHD
Brief: Lumos Pharma To Host Kol Webinar To Discuss Interim Phase 2 Data From Oragrowth Trials In Pghd
U.S. RESEARCH ROUNDUP-Calithera Biosciences, Haynes International, Lumos Pharma
Lumos Pharma Inc reports results for the quarter ended in September - Earnings Summary
Lumos slides as height growth drug underperforms existing hormone therapy in trial
Brief: Lumos Pharma Reports Q3 loss Of $0.86 Per Share
Brief: Lumos Pharma Announces Encouraging Interim Mid-stage Study Results For Pediatric Growth Drug
Lumos Pharma Inc expected to post a loss of $1.01 a share - Earnings Preview
Lumos Pharma Inc expected to post a loss of $1.01 a share - Earnings Preview
Lumos Pharma Inc expected to post a loss of $1.01 a share - Earnings Preview
Brief: Lumos Pharma Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: Lumos Pharma announces share repurchase program
Lumos Pharma Inc reports results for the quarter ended in June - Earnings Summary
U.S. RESEARCH ROUNDUP- Brunswick, Hasbro, Seaworld Entertainment